• DOI:10.1002/ana.21394
• Corpus ID: 41546628

Chronic toxic encephalopathy caused by occupational solvent exposure

@article{Baker2008ChronicTE,
  title={Chronic toxic encephalopathy caused by occupational solvent exposure},
  author={Edward L. Baker},
  journal={Annals of Neurology},
  year={2008},
  volume={63}
}

• E. Baker
• Published 1 May 2008
• Biology
• Annals of Neurology

References 1. Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York: Oxford University Press, 2001. 2. Patel K, Muntoni F. Inducing muscle hypertrophy as a therapeutic strategy for muscular dystrophies. 122nd ENMC International Workshop, Naarden, The Netherlands, 28-30 November 2003. Neuromuscul Disord 2004;14:519–525. 3. Patel K, Amthor H. The function of myostatin and strategies of myostatin blockade—new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 2005;15: 117–126. 4. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83–90. 5. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 2006;312:2401–2414. 6. Amthor H, Huang R, McKinnell I, et al. The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol 2002;251: 241–257. 7. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006;209:501–514. 8. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997;17:71–74. 9. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002;52:832–836. 10. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418–421. 11. Li ZF, Shelton GD, Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 2005;166:491–497. 12. Parsons SA, Millay DP, Sargent MA, et al. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006; 168:1975–1985. 13. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63:561–571. 14. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid -glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99–109. 15. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001;98:9306–9311. 16. Karpati G, Carpenter S. Small-caliber skeletal muscle fibers do not suffer deleterious consequences of dystrophic gene expression. Am J Med Genet 1986;25:653–658. 17. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007;20:590–594.